Additionally, due to the lack of access to validated data for breast cancer, we used TISIDB database (http://cis.hku.hk/TISIDB/index.php) [47] to evaluate whether METTL3 and IGF2BP3 showed differential expression in clinical data between responders and non-responders undergoing anti-PD-1/PD-L1 treatment. The gene discussed is METTL3; the disease is breast cancer.